Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McConkey

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|June 27, 2024
Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experienceEvangelia Vlachou, Burles Avner Johnson, David McConkey, et al.
European Urology Open Science|February 23, 2023
Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the LiteratureEvangelia Vlachou, Andres Matoso, David McConkey, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phaseFabio P S Santos, Hagop Kantarjian, David McConkey, et al.
The Journal of Urology|April 18, 2007
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancerLiana Adam, Peter C Black, Wassim Kassouf, et al.
Clinical Genitourinary Cancer|December 28, 2020
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective ExperienceJean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapyLiana Adam, Meng Zhong, Woonyoung Choi, et al.
Cancer Research|February 20, 2003
Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cellsXinqiao Zhang, Asha S Multani, Jain-Hua Zhou, et al.
The Journal of Urology|January 9, 2018
Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial CarcinomaRoss S Liao, Mohit Gupta, Zeyad R Schwen, et al.
European Urology|November 5, 2021
A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder CancerWoonyoung Choi, Kara Lombardo, Sunil Patel, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|June 27, 2024
Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experienceEvangelia Vlachou, Burles Avner Johnson, David McConkey, et al.
European Urology Open Science|February 23, 2023
Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the LiteratureEvangelia Vlachou, Andres Matoso, David McConkey, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phaseFabio P S Santos, Hagop Kantarjian, David McConkey, et al.
The Journal of Urology|April 18, 2007
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancerLiana Adam, Peter C Black, Wassim Kassouf, et al.
Clinical Genitourinary Cancer|December 28, 2020
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective ExperienceJean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapyLiana Adam, Meng Zhong, Woonyoung Choi, et al.
Cancer Research|February 20, 2003
Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cellsXinqiao Zhang, Asha S Multani, Jain-Hua Zhou, et al.
The Journal of Urology|January 9, 2018
Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial CarcinomaRoss S Liao, Mohit Gupta, Zeyad R Schwen, et al.
European Urology|November 5, 2021
A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder CancerWoonyoung Choi, Kara Lombardo, Sunil Patel, et al.
Pageof 8